Terms of Service
Effective date: March 11, 2026
Last updated: March 11, 2026
Agreement to Terms
These Terms of Service ("Terms") govern your access to and use of eyeView, the AI-powered visual intelligence platform operated by Nucleus Software ("we", "us", "our"). By accessing or using eyeView at eyeview.pro or app.eyeview.pro, you agree to be bound by these Terms. If you do not agree to these Terms, do not use the service.
Description of Service
eyeView is a visual intelligence platform designed for packaging review and approval workflows. The service includes tools for uploading, comparing, annotating, and approving packaging artwork, as well as AI-powered visual analysis and version tracking.
Account Registration
To use eyeView, you must create an account and provide accurate, complete information. You are responsible for maintaining the security of your account credentials and for all activities that occur under your account. You must notify us immediately of any unauthorized use of your account.
Subscription and Billing
Some features of eyeView require a paid subscription. By subscribing to a paid plan, you agree to pay the applicable fees as described at the time of purchase. Subscriptions automatically renew unless cancelled before the renewal date. We reserve the right to change pricing with 30 days' notice.
Refunds are handled on a case-by-case basis. Contact us at suporte@eyeview.pro for billing inquiries.
Acceptable Use
You agree not to:
- Use eyeView for any unlawful purpose or in violation of any applicable laws
- Upload content that infringes on intellectual property rights of others
- Attempt to gain unauthorized access to our systems or other users' accounts
- Interfere with or disrupt the platform or servers connected to it
- Use automated systems (bots, scrapers) to access the platform without permission
- Reverse engineer, decompile, or disassemble any part of the service
- Resell, sublicense, or redistribute access to eyeView without authorization
Intellectual Property
eyeView, including its design, features, code, and documentation, is owned by Nucleus Software and protected by intellectual property laws. Your subscription grants you a limited, non-exclusive, non-transferable license to use the platform for its intended purpose.
Your Content and Data
You retain ownership of all content you upload to eyeView, including artwork, documents, and feedback. By uploading content, you grant us a limited license to store, process, and display it as necessary to provide the service. We will not use your content for any purpose other than delivering the eyeView service to you.
Limitation of Liability
To the maximum extent permitted by law, Nucleus Software shall not be liable for any indirect, incidental, special, consequential, or punitive damages, or any loss of profits or revenues, whether incurred directly or indirectly, or any loss of data, use, or goodwill. Our total liability for any claims arising from these Terms or the use of eyeView shall not exceed the amount you paid us in the 12 months preceding the claim.
Disclaimer of Warranties
eyeView is provided "as is" and "as available" without warranties of any kind, whether express or implied, including but not limited to implied warranties of merchantability, fitness for a particular purpose, and non-infringement. We do not guarantee that the service will be uninterrupted, secure, or error-free.
Termination
You may cancel your account at any time. We may suspend or terminate your access to eyeView if you violate these Terms or for any other reason with reasonable notice. Upon termination, your right to use the platform ceases immediately. We will make your data available for export for 30 days after termination.
Governing Law
These Terms shall be governed by and construed in accordance with the laws of Brazil, without regard to its conflict of law provisions. Any disputes arising from these Terms shall be resolved in the courts of Gaspar, Santa Catarina, Brazil.
Changes to Terms
We reserve the right to modify these Terms at any time. We will provide notice of significant changes via email or a prominent notice within the platform. Your continued use of eyeView after changes take effect constitutes acceptance of the revised Terms.
Contact Us
If you have questions about these Terms, please contact us at: